What is the current stock price of CareDx, Inc (CDNA)?

As of the latest market data, CareDx, Inc (CDNA) is trading at $21.42. The stock has seen a loss of -4.46% today.

Does CareDx, Inc (CDNA) pay a dividend?

Based on current data, CareDx, Inc does not have a confirmed active dividend policy.

What is the market cap of CareDx, Inc?

The current market capitalization of CareDx, Inc (CDNA) is approximately unavailable.

CDNA

CareDx, Inc·Healthcare

21.42

4.460%(−1.00)

Market Closed

25.00

16.713%(+3.58)

After Hours

Last Updated: — ET

52W L: $10.9652W H: $23.24

CDNA NEWS

zacks.com

23h ago

All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy

CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

benzinga.com

1d ago

CareDx Sharpens Focus On Core Testing Services

The transaction, approved by both companies' boards, is expected to close by the end of the third quarter of 2026.

globenewswire.com

2d ago

Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division

EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's ‘lab products' portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market Acceleration of Eurobio's strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading provider of kits for transplantation genomics Acquisition of a 100% proprietary products portfolio Deeper capabilities and larger scale with technological and commercial complementarities Paris, April 16, 2026 ,8 AM EST Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro medical diagnostics for transplantation, oncology and infectious diseases, today announces that it has entered into a definitive agreement to acquire the Lab Products division of CareDx, a US global precision medicine company focused on transplantation. Through the acquisition of CareDx's Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA)” typing and transplantation diagnostics.

businesswire.com

2d ago

CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for cash consideration of $170 million. The transaction has been approved by the boards.

businesswire.com

3d ago

CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.

defenseworld.net

Mar 16

Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA

Bamco Inc. NY grew its stake in shares of CareDx, Inc. (NASDAQ: CDNA) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,155,180 shares of the company's stock after buying an additional 719,523 shares during the period. Bamco

Company Profile

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

644

IPO Date

2014-07-17

Beta

2.54

Websitewww.caredx.com↗